Category: Other
Objective: The purpose of this study is determinate the efficacy and safety of botulin toxin A in the treatment of refractory post herpetic neuralgia and trigeminal neuralgia.The purpose of this study is determinate the efficacy and safety of botulin toxin A in the treatment of refractory post herpetic neuralgia and trigeminal neuralgia.
Background: trigeminal neuralgia (TN) and postherpetic neuralgia (PHN) are two of the most painfully disease and one of the most common consulting with the neurologist, neurosurgeon, maxillofacial specialist. in Guatemalan population the option are limitaded to antiepileptic drugs, opioids an steroids. Characterized by paroxysmal facial pain attacks in TN and local dermatomes pain in PHN, drugs therapies often limited are by the lack of efficacy and intolerance due to central nervous system side effects. The aim of this study is to discuss the efficacy and safety option Subcutaneous injections and/or submucosal injections of Botulinum Toxin Type A (BTX-A).
Method: Material and Methods: we use the treatment incobotulinumtoxinA 50ui in 19 patients in in the corresponding branch of the trigeminal nerve as well as in the dermatome affected by post herpetic pain. The second dose administered was 6 weeks after the first administration of botulinum toxin. The result assessed was according to the Numeric rating scales (NRS) pain scale at 6 weeks after the first dose and at 6 weeks after the second dose.
Results: Results: The decrease in pain after the first administration was 4 points less according to the NRS scale and after the second dose 3 points less according to the NRS scale on average for all patients. The most common adverse effect was transient pain upon administration of botulinum toxin, headache, and in 1 case, transient paralysis of the orbicularis oris muscle in the region administered.
Conclusion: Conclusions: the administration of incobotulinumtoxinA in patients with trigeminal neuralgia and in patients with post-herpetic pain is effective in reducing the intensity of pain and is a safe treatment in patients with these symptoms.
To cite this abstract in AMA style:
F. Ortega. Botulinum Toxin A in the Management of peripheral mononeuropathy: post herpetic neuralgia and trigeminal neuralgia [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/botulinum-toxin-a-in-the-management-of-peripheral-mononeuropathy-post-herpetic-neuralgia-and-trigeminal-neuralgia/. Accessed July 10, 2025.« Back to 2022 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/botulinum-toxin-a-in-the-management-of-peripheral-mononeuropathy-post-herpetic-neuralgia-and-trigeminal-neuralgia/